

**OPTN Histocompatibility Committee
Meeting Summary
February 11, 2024
Webex Meeting**

**Gerald Morris, MD, Chair
Kelley Hitchman, PhD, MS, Vice Chair**

Introduction

The Histocompatibility Committee (“Committee”) met via WebEx teleconference on 02/11/2025 to discuss the following agenda items:

1. 2022 HLA Tables 2-Year Monitoring Report
2. Guidance Document Discussion
3. Next Steps

The following is a summary of the Committee’s discussions.

1. 2022 HLA Tables 2-Year Monitoring Report

No decisions were made.

Summary of Presentation:

A research staff member presented the two-year monitoring report for the Human Leukocyte Antigen (HLA) tables implemented in 2022. This implementation included the addition of equivalency table for HLA-DPA1 and updates of HLA-DPB1 equivalences and reportable values. Staff reviewed the cohort of kidney, kidney-pancreas, and pancreas waitlist registrations and organ recoveries.

Included in the report:

- ~15% increase in reporting of DPA1 for deceased kidney and pancreas donors
- Large increases of reporting of DPA1 for waitlist additions
- Most commonly reported typing for registrations added was DPA1*01:03
- Registrations added in post-policy era rarely called unacceptable antigens for DPA1
- Most commonly called unacceptable antigen was HLA-DPA1*02
- Little difference in reporting of DPB1 between eras for kidney and pancreas donors
- Most common reported DPB1 typing for donors was 04:01
- Large increase in reporting for DPB1 for additions to waiting list
- HLA-DPB1*04:01 was the most common reporting typing for waitlist additions
- Decreases seen in reporting of unacceptable antigens for DPB1 for all organ groups
- HLA-DPB1*6:01 was the most common typing to have an unacceptable antigen called
- .5% decrease for pancreas matches

2. Center for Medicare and Medicaid (CMS) – Guidance Document Discussion

No decisions were made.

Summary of Presentation:

Leadership presented options for the CMS guidance document update to adjust language around periodic sample collection. The proposed language is as follows:

“The frequency of periodic sample collection: It is recommended that laboratories have monthly serum samples for candidates and use these samples to develop an antibody history and facilitate final crossmatches. Determination of the specific schedule for sample collection, storage, and testing is ultimately determined by the transplant programs and laboratories”

Summary of Discussion:

A member asked if the language should specify “active candidates.” Some members spoke in support, while another member added that reactivated candidates may get offers quickly, and if the candidates did not get monthly serum samples while inactive, their testing may lag. Members decided to keep language around active status out of the official guidance statement.

3. Next Steps

No decisions were made.

Summary of Presentation:

Leadership presented the upcoming table update project, which is projected to include an update to Table 4-16 and a status change of C*04:09 from null to low-expression. The Committee discussed options for notifying the histocompatibility community on this status change. They also discussed potential impacts of this status change and its subsequent reporting, which may include discussions with vendors about updated testing.

Upcoming Meeting

- March 25, 2025

Attendance

- **Committee Members**
 - Helene McMurray
 - Julie Houp
 - Michael Gautreaux
 - Dave Pinelli
 - John Lunz
 - Mike Hurtik
 - Qingyong Xu
 - Ryan Pena
 - Darryl Nethercot
 - Bobbie Rhodes-Clark
 - Crystal Usenko
 - Kelley Hitchman
 - Hemant Parekh
 - Tiffany Bratton
 - Jerome Saltarelli
 - Jerry Morris
- **SRTR Staff**
 - Rajalingam Raja
- **UNOS Staff**
 - Jamie Panko
 - Betsy Gans
 - Matt Cafarella
 - Thomas Dolan
 - Laura Schmitt
 - Amelia Deveraux